ArticleThe American journal of pathology1999
Insulin-like growth factor I reverses experimental diabetic autonomic neuropathy.
Article in The American journal of pathology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 85 citations in OpenAlex.
- Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions.Brain sciences · 2023Review
- IGF-1 signaling via the PI3K/Akt pathway confers neuroprotection in human retinal pigment epithelial cells exposed to sodium nitroprusside insult.Journal of molecular neuroscience : MN · 2015Article
- Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.Endocrine, metabolic & immune disorders drug targets · 2012Review
- Animal models of peripheral neuropathies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2012Review
- Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia.Experimental neurology · 2011Article
- Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies.The American journal of pathology · 2010Article
- Cellular pathogenesis of diabetic gastroenteropathy.Minerva gastroenterologica e dietologica · 2009Review
- Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy.Stem cells (Dayton, Ohio) · 2009Article
- Insulin-like growth factors in the peripheral nervous system.Endocrinology · 2008Review
- Diabetic neuropathy: mechanisms to management.Pharmacology & therapeutics · 2008Review
- Neurotrophic factors in autonomic nervous system plasticity and dysfunction.Neuromolecular medicine · 2008Review
- Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice.Experimental neurology · 2008Article
- Role of insulin-like growth factor I signaling in neurodegenerative diseases.Journal of molecular medicine (Berlin, Germany) · 2004Review
- Comparative neuropathology and diabetic autonomic neuropathy.The American journal of pathology · 2003Article
- Non-obese diabetic mice rapidly develop dramatic sympathetic neuritic dystrophy: a new experimental model of diabetic autonomic neuropathy.The American journal of pathology · 2003Article
- Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy.The American journal of pathology · 2003Article
- Oxidative stress and diabetic neuropathy: a new understanding of an old problem.The Journal of clinical investigation · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Recent studies have suggested a role for neurotrophic substances in the pathogenesis and treatment of diabetic neuropathy. In this study, the effect of insulin-like growth factor I (IGF-I) on diabetic sympathetic autonomic neuropathy was examined in an experimental streptozotocin-induced diabetic rat model. Two months of IGF-I treatment of chronically diabetic rats with established neuroaxonal dystrophy (the neuropathological hallmark of the disease) involving the superior mesenteric ganglion and ileal mesenteric nerves resulted in nearly complete normalization of the frequency of neuroaxonal dystrophy in both sites without altering the severity of diabetes. Treatment with low-dose insulin (to control for the transient glucose-lowering effects of IGF-I) failed to affect the frequency of ganglionic or mesenteric nerve neuroaxonal dystrophy or the severity of diabetes. The striking improvement in the severity of diabetic autonomic neuropathy shown with IGF-I treatment in these studies and the fidelity of the rat model to findings in diabetic human sympathetic ganglia provide promise for the development of new clinical therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.